Biotech

All Articles

A closer look at Ferocious Biotech's Intense 15

.In this week's episode of "The Top Line," our experts are actually diving right into Fierce Biotech...

Lilly experiences period 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's gathering commemorating the commendation of ...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of notable leadership hirings, firings as we...

Lykos will ask FDA to reconsider its selection adhering to turndown of MDMA therapy for trauma

.Complying with an inadequate presenting for Lykos Therapies' MDMA applicant for trauma at a recent ...

AN 2 halves roll call, quits phase 3 test after records disappoint

.AN2 Rehabs is reassessing its company in response to uninspired midphase data, vowing to lay off ha...

Merck spends $700M for bispecific, snooping autoimmune opening as well as chance to test Amgen in cancer

.Merck &amp Co. is spending $700 thousand upfront to challenge Amgen in a blood cancer cells market....

Gilead pays out J&ampJ $320M to exit licensing deal for seladelpar

.With Gilead Sciences about to an FDA choice for its own liver ailment drug seladelpar, the company ...

' All palms on deck' at Lilly as peers target weight problems market

.CEO David Ricks can easily view the companies putting together camping tents at basecamp behind Eli...

Entero laying off personnel, vacating office and stopping R&ampD

.Cushion Liquidators has transformed Entero Therapeutics white as a slab. The lender bought Entero t...

Exelixis loses ADC after determining it is actually no suit for Tivdak

.Exelixis is losing hope on its cells factor (TF)- targeting antibody-drug conjugate after wrapping ...